Skip to main content

Pressure BioSciences Aims to Raise $5M to Regain Compliance with Nasdaq Listing Requirements


This article was originally posted on June 14.

Pressure BioSciences said today it has received a notice from Nasdaq granting it an extension until Oct. 3 to regain compliance with the exchange's minimum stockholder equity requirement of $2.5 million.

According to a plan submitted by PBI to Nasdaq on May 23, to regain compliance and remain above the requirement for the foreseeable future, the company will need to raise at least $5 million in additional equity capital. The company was first notified it had fallen out of compliance on April 6.

On April 13, PBI announced it had raised $825,720 in gross proceeds from the sale of 55,048 units to 10 accredited investors including president and CEO Richard Schumacher, in the first tranche of its $6 million Series C private placement.

This tranche "took months longer than expected to close," Schumacher noted in a statement accompanying the raise, estimating that proceeds from the round would "enable [the company] to fund existing operations to approximately June 30, 2011."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.